Advertisement
UK markets close in 3 hours 1 minute

  • FTSE 100

    8,223.91
    +18.80 (+0.23%)
     

  • FTSE 250

    20,433.27
    +52.22 (+0.26%)
     

  • AIM

    773.86
    -3.64 (-0.47%)
     

  • GBP/EUR

    1.1828
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2686
    -0.0035 (-0.28%)
     

  • Bitcoin GBP

    52,014.04
    +701.73 (+1.37%)
     

  • CMC Crypto 200

    1,376.68
    -5.99 (-0.43%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CRUDE OIL

    81.59
    +0.02 (+0.02%)
     

  • GOLD FUTURES

    2,353.20
    +6.30 (+0.27%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     

  • DAX

    18,144.63
    +76.72 (+0.42%)
     

  • CAC 40

    7,623.43
    +53.23 (+0.70%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

Amneal to Participate at Upcoming Investor Conference

Business Wire
·1-min read

BRIDGEWATER, N.J., May 22, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.

Chirag will present at 1:30 PM EST. A live webcast of the presentation will be accessible on the Company's website at https://investors.amneal.com. A replay of the webcast will be available following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 generic and specialty pharmaceuticals, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522763089/en/

Contacts

Investor Contact:
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com